(Wang Aibing Wang Zhenya, a reporter from the Peoples Daily Health Client Wang Aibing) "Generally speaking, the negotiation results are basically a considerable reduction. Although the price is different from the expected gap, it is also within a range of acceptable."At 13:30 on October 28th, after walking out of the National Peoples Congress Center, after a short-term internal summary meeting, Vice President of China Huang Bin accepted the exclusive exclusive reporter of the Peoples Daily Health Client.Interview.
2024 National Medical Insurance negotiation site, Wang Zhenya Photo
October 28 is 2024, 2024, 2024, 2024On the second day of the National Medical Insurance negotiations, the reporter learned that the varieties of negotiations on the day were mainly focused on drugs, anti-cancer drugs, etc. From the situation in the morning, the negotiation process of multiple pharmaceutical companies was compared withAnxious.By negotiating with "Solo Miao New Medicine", bluntly stressed
He has participated in 26 consecutive years in the past 7 years 26Huang Bin, who negotiated the medical insurance, only had one new drug negotiation task this year, but two days before the negotiations began this year, Huang Bin bluntly said to reporters, "This years negotiations are under great pressure, because there is only one innovative drug participating in the negotiations.It is a very, very important variety in the future.(Decobuzumab was used for injection).
In February 2023, the injection was first approved for listing in China for injection in China. It was used for single-drug treatment HER2 positive late-stage HER2 positive patients; subsequent approval of the treatment of at least one systematic treatment in the past during the metastatic stage, or the HER2 low that recurred within 6 months after the auxiliary chemotherapy period or completed the auxiliary chemotherapy periodExpression (IHC 1+ or IHC 2+/ISH-) patients with advanced breast cancer; HER2 positive advanced stomach or gastroesophageal adenocarcinoma patients who have received two or more treatment schemes in the treatment; Her2 (ERBB2) has HER2 (ERBB2).A total of four indications for activating mutations and previously received at least one systematic treatment that has been treated with at least one systematic treatment. There are four indications in total.Indications in the field of treatment.
"We will not enter the negotiating site at about 12 oclock. Like each negotiation, the two parties have quoted many times in accordance with the rules and processes of the negotiations, and also launched a concise and effective consultation and communication.The core of the negotiation is the process of quotation, especially the first two rounds of offer, which is the most tense and challenging part in negotiations. "Huang Bin said frankly.In the past two years, there have been many market comparative analysis, calculation of drug economics, and understanding of clinical usage.Encouragement of innovative medicines
Participated in many medical insurance negotiations, Huang Bin introduced, "From the perspective of the negotiation process, the overall changes have not changed much in these years.The guiding role of the enterprise is becoming more and more obvious, and it is very helpful for the level of negotiating price to determine the negotiation price. It is a very important part of medical insurance negotiation work.The team leader, different team leaders have different styles, but no matter what style, each team leader shows a strong sense of responsibility and professionalism.. "
" The technological value of Decorzumab is very high, I hope that all teachers can give more recognition of this medicine value. "Huang Bin told reporters,At the negotiation site, he has always showed the innovation of drugs to the experts of experts. "In fact, years of negotiating experience has also made me feel that the encouragement and support of innovative drugs in the country and medical insurance departments is increasing. For innovative drugs,In particular, the drugs, the research and data of the drug economics for the first negotiations are also playing an increasing role. The negotiations are becoming more and more based on the analysis of comprehensive and in -depth pharmaceutical economics.Predicted "
